A Multi-Center, Open-label Phase Ib-II Trial of the Combination of GX-188E Vaccination and Pembrolizumab in Patients With Advanced, Non-Resectable HPV Type 16 and/or 18 Positive Cervical Cancer
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 02 Apr 2018
At a glance
- Drugs GX 188E (Primary) ; Pembrolizumab (Primary)
- Indications Cervical cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genexine
- 19 Feb 2018 Status changed from planning to not yet recruiting.
- 19 Jun 2017 According to a Genexine media release, the Ministry of Food and Drug Safety (MFDS) in Korea has granted approval to initiate this trial.
- 28 Nov 2016 New trial record